{"gene":"ARFIP1","run_date":"2026-06-14T20:59:48+00:00","timeline":{"discoveries":[{"year":1997,"finding":"Arfaptin-1 was identified as a cytosolic binding partner of GTP-bound class I ARFs (especially ARF1) via yeast two-hybrid screening; it binds preferentially to the GTP-bound form of ARF1/ARF3 independent of ARF myristoylation, and is recruited from cytosol to Golgi membranes in a GTPγS-dependent, brefeldin A-sensitive manner. When expressed in COS cells, arfaptin-1 localizes to the Golgi complex.","method":"Yeast two-hybrid, recombinant protein binding assays, subcellular fractionation, COS cell overexpression with immunofluorescence","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal binding assays, subcellular fractionation, and localization in multiple systems; foundational paper replicated by subsequent work","pmids":["9038142"],"is_preprint":false},{"year":1998,"finding":"Arfaptin-1 inhibits ARF1/ARF3-stimulated phospholipase D and cholera toxin ADP-ribosyltransferase activities in a concentration-dependent manner in vitro; inhibition requires the N-terminal region of ARF1, and arfaptin-1 has minimal effects on guanine nucleotide binding to ARFs or on GEF/GAP activity.","method":"In vitro enzymatic assays with recombinant proteins, ARF deletion/mutant analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro enzymatic assays with mutagenesis controls, replicated in subsequent papers","pmids":["9694811"],"is_preprint":false},{"year":1999,"finding":"Arfaptin-1 overexpression in NIH 3T3 cells inhibits phorbol ester-stimulated phospholipase D activity and ARF activation of Golgi-associated PLD; overexpression also decreases the rate of ER-to-Golgi protein transport (VSV-G glycosylation assay), approximately two-fold.","method":"Overexpression in NIH 3T3 cells, PLD activity assay, VSV-G glycosylation transport assay","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-based loss-of-function/gain-of-function with defined cellular readouts, single lab","pmids":["9989604"],"is_preprint":false},{"year":1999,"finding":"Arfaptin-1 associates with high-speed membranes independently of ARF, and myristoylated ARF3 enhances this membrane association, indicating formation of an arfaptin-1/ARF complex on Golgi membranes. Deletion mutagenesis identified two binding sites on arfaptin-1 required for both ARF3 association and inhibition of PLD activation.","method":"Membrane fractionation, co-immunoprecipitation, deletion mutagenesis, in vitro PLD assay","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — membrane fractionation with deletion mutants and in vitro PLD assay, single lab","pmids":["10413101"],"is_preprint":false},{"year":2003,"finding":"Arfaptin-1 overexpression inhibits PMA-stimulated MMP-9 secretion and PLD activation in HT1080 fibrosarcoma cells, placing arfaptin-1 upstream of ARF-dependent PLD activation in phorbol ester-stimulated secretion.","method":"Overexpression in HT1080 cells, MMP-9 secretion assay, PLD activity assay","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — overexpression with defined secretion readout, consistent with prior mechanistic work, single lab","pmids":["12606037"],"is_preprint":false},{"year":2005,"finding":"Only GTP-bound forms of Arf1, Arf5, and Arf6 interact with arfaptin-1 (GTP-Arf1 showing strongest binding); neither GTP-Rac1 nor GDP-Rac1 binds arfaptin-1, distinguishing arfaptin-1 from arfaptin-2 which binds GDP-Rac1.","method":"In vitro binding assays with GTP- and GDP-liganded Arf and Rac1 isoforms","journal":"Methods in enzymology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct in vitro binding assays with nucleotide-loaded GTPases, single lab, methods chapter","pmids":["16413282"],"is_preprint":false},{"year":2011,"finding":"Arfaptins (including arfaptin-1) associate with trans-Golgi membranes via their BAR domain interacting with Arl1 (not ARFs); arfaptins compete with golgin-97 and golgin-245 for Arl1 binding. Time-lapse imaging shows arfaptin-1 (but not golgin-97) is incorporated into vesicular and tubular structures emanating from the Golgi, indicating a role in membrane deformation at the TGN.","method":"Co-immunoprecipitation, BAR domain deletion mutants, siRNA knockdown, time-lapse fluorescence microscopy","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, domain mapping, live imaging, multiple orthogonal methods in one study","pmids":["21239483"],"is_preprint":false},{"year":2012,"finding":"Protein kinase D (PKD) phosphorylates arfaptin-1 at serine 132, disrupting its ability to inhibit ARF activity and thereby controlling scission of nascent secretory granules at the TGN. Non-phosphorylatable arfaptin-1 (S132A) causes granule scission defects in pancreatic β cells and abolishes glucose-stimulated insulin secretion; arfaptin-1 depletion generates small, non-functional secretory granules.","method":"In vitro kinase assay, phosphomimetic/phospho-deficient mutagenesis, RNAi knockdown, insulin secretion assay, electron microscopy of β cells","journal":"Developmental cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro kinase assay with mutagenesis, RNAi, and functional secretion readout in multiple cell types; replicated in commentary","pmids":["22981988"],"is_preprint":false},{"year":2015,"finding":"Arfaptin-1 negatively regulates Arl1-mediated retrograde transport from endosomes to the Golgi (Shiga toxin subunit B assay); knockdown of arfaptin-1 accelerates retrograde transport, while overexpression inhibits it. An Arl1-binding-defective mutant (arfaptin-1b-F317A) fails to inhibit transport, establishing that Arl1 interaction is required. The N-terminal region of arfaptin-1 is involved in retrograde transport regulation.","method":"siRNA knockdown, overexpression of WT and Arl1-binding-defective mutants, Shiga toxin subunit B retrograde transport assay, differential affinity chromatography/mass spectrometry","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function and gain-of-function with defined transport assay, mutant rescue experiment, and biochemical identification of interaction","pmids":["25789876"],"is_preprint":false},{"year":2017,"finding":"BAR-domain-containing arfaptin-1/2 are recruited to tubular membrane intermediates at the TGN and guide clathrin/AP-1-coated carrier scission, downstream of PIP5K1A/PLC-β3-mediated lipid conversion and F-actin-based membrane tubulation.","method":"In vitro reconstitution, quantitative proteomics, lipidomics, in vivo cell-based assays","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution and proteomics, but arfaptin-1 specific contribution not isolated from arfaptin-2 in single study","pmids":["28854360"],"is_preprint":false}],"current_model":"Arfaptin-1 is a BAR-domain-containing cytosolic protein that is recruited to the trans-Golgi network by binding GTP-Arf1 (and related class I ARFs) and Arl1; it inhibits ARF-stimulated phospholipase D and ARF-dependent vesicle scission, thereby acting as a checkpoint that delays secretory granule scission at the TGN until protein kinase D phosphorylates it at serine 132, releasing ARF inhibition and allowing scission to proceed, and it also negatively regulates Arl1-mediated retrograde endosome-to-Golgi transport through its BAR domain."},"narrative":{"mechanistic_narrative":"Arfaptin-1 (ARFIP1) is a cytosolic BAR-domain protein that functions at the trans-Golgi network as a GTPase-effector regulator of membrane deformation and carrier scission in the secretory and retrograde transport pathways [PMID:9038142, PMID:21239483]. It was first defined as a selective effector of GTP-bound class I ARFs, binding preferentially to the activated, GTP-loaded forms of ARF1/ARF3 (and ARF5/ARF6) independent of myristoylation and translocating from cytosol to Golgi membranes in a GTPγS-dependent, brefeldin A-sensitive manner [PMID:9038142, PMID:16413282]. Through this interaction it acts as a negative regulator of ARF function, inhibiting ARF-stimulated phospholipase D and cholera toxin ADP-ribosyltransferase activities in a manner requiring the ARF N-terminus, and dampening ARF/PLD-dependent secretory output in cells [PMID:9694811, PMID:9989604, PMID:12606037]. At the TGN its BAR domain additionally binds Arl1—competing with golgins for this site—and incorporates arfaptin-1 into nascent vesicular and tubular carriers, where it negatively regulates Arl1-dependent retrograde endosome-to-Golgi transport and contributes to clathrin/AP-1 carrier scission downstream of phosphoinositide conversion and actin-based tubulation [PMID:21239483, PMID:25789876, PMID:28854360]. Arfaptin-1 operates as a scission checkpoint: protein kinase D phosphorylates it at serine 132 to relieve its inhibition of ARF activity, and loss of this regulation produces secretory granule scission defects and abolishes glucose-stimulated insulin secretion in pancreatic β cells [PMID:22981988].","teleology":[{"year":1997,"claim":"Established arfaptin-1 as a bona fide ARF effector by showing it is a cytosolic protein that selectively recognizes the activated state of class I ARFs and is recruited to the Golgi accordingly.","evidence":"Yeast two-hybrid, recombinant binding assays, subcellular fractionation, and COS-cell immunofluorescence","pmids":["9038142"],"confidence":"High","gaps":["Did not define the functional consequence of ARF binding","BAR-domain structural basis of membrane recruitment not addressed"]},{"year":1998,"claim":"Defined arfaptin-1 as a negative regulator of ARF enzymatic output, showing it inhibits ARF-stimulated PLD and ADP-ribosyltransferase without altering ARF nucleotide cycling.","evidence":"In vitro enzymatic assays with recombinant proteins and ARF deletion/mutant analysis","pmids":["9694811"],"confidence":"High","gaps":["Cellular relevance of in vitro inhibition not yet established","Mechanism by which the ARF N-terminus mediates inhibition unresolved"]},{"year":1999,"claim":"Connected arfaptin-1's ARF/PLD inhibition to cellular transport and secretion, and mapped the arfaptin-1 regions required for ARF binding and inhibition.","evidence":"Overexpression in NIH 3T3 and HT1080 cells with PLD, VSV-G glycosylation, and MMP-9 secretion readouts; membrane fractionation with deletion mutants","pmids":["9989604","10413101"],"confidence":"Medium","gaps":["Effects rely on overexpression in single labs","Whether endogenous arfaptin-1 sets the same set-point not tested"]},{"year":2005,"claim":"Refined effector specificity, confirming arfaptin-1 binds only GTP-loaded ARFs and not Rac1, distinguishing it from the GDP-Rac-binding paralog arfaptin-2.","evidence":"In vitro binding assays with nucleotide-loaded Arf and Rac1 isoforms","pmids":["16413282"],"confidence":"Medium","gaps":["Methods-chapter data from a single lab","Functional consequence of isoform-specific binding not addressed"]},{"year":2011,"claim":"Identified a distinct BAR-domain-dependent Arl1 interaction and direct role in membrane deformation, repositioning arfaptin-1 as a carrier-shaping factor at the TGN rather than purely an ARF inhibitor.","evidence":"Co-IP, BAR-domain deletion mutants, siRNA knockdown, and time-lapse imaging of Golgi carriers","pmids":["21239483"],"confidence":"High","gaps":["How ARF binding and Arl1 binding are coordinated unclear","Cargo carried by arfaptin-positive carriers not defined"]},{"year":2012,"claim":"Revealed the regulatory switch controlling arfaptin-1 activity, showing PKD phosphorylation at Ser132 relieves ARF inhibition to permit secretory granule scission, with physiological consequences for insulin secretion.","evidence":"In vitro kinase assay, phospho-mutant analysis, RNAi, insulin secretion assay, and EM of β cells","pmids":["22981988"],"confidence":"High","gaps":["Structural effect of Ser132 phosphorylation on the ARF-binding surface not resolved","Whether the same switch governs constitutive (non-granule) carriers untested"]},{"year":2015,"claim":"Extended arfaptin-1 function to the retrograde pathway, demonstrating it negatively regulates Arl1-dependent endosome-to-Golgi transport via a required Arl1-binding interface.","evidence":"siRNA knockdown, WT/Arl1-binding-defective mutant rescue, Shiga toxin B retrograde assay, and affinity chromatography/MS","pmids":["25789876"],"confidence":"High","gaps":["Mechanism linking Arl1 binding to retrograde rate control unclear","Interplay between anterograde scission and retrograde regulation not integrated"]},{"year":2017,"claim":"Placed arfaptins within a lipid- and actin-driven carrier biogenesis pathway, showing BAR-domain recruitment guides clathrin/AP-1 carrier scission downstream of phosphoinositide conversion and F-actin tubulation.","evidence":"In vitro reconstitution, quantitative proteomics, lipidomics, and cell-based assays","pmids":["28854360"],"confidence":"Medium","gaps":["Arfaptin-1-specific contribution not separated from arfaptin-2","Quantitative ordering of lipid, actin, and BAR steps not fully resolved"]},{"year":null,"claim":"How arfaptin-1's two GTPase interfaces (GTP-ARF inhibition versus Arl1/BAR-domain membrane shaping) are spatially and temporally coordinated at the TGN, and the structural basis of the PKD-phosphorylation switch, remain open.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structure of arfaptin-1 bound to ARF or Arl1 in the corpus","Endogenous cargo selectivity of arfaptin-1 carriers undefined","Non-secretory physiological roles uncharacterized"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[1,2,7]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[6,9]},{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[6,9]}],"localization":[{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[0,6]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0]}],"pathway":[{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[6,7,8,9]},{"term_id":"R-HSA-9609507","term_label":"Protein localization","supporting_discovery_ids":[8]}],"complexes":[],"partners":["ARF1","ARF3","ARL1","PRKD1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P53367","full_name":"Arfaptin-1","aliases":["ADP-ribosylation factor-interacting protein 1"],"length_aa":373,"mass_kda":41.7,"function":"Plays a role in controlling biogenesis of secretory granules at the trans-Golgi network (PubMed:22981988). Mechanistically, binds ARF-GTP at the neck of a growing secretory granule precursor and forms a protective scaffold (PubMed:22981988, PubMed:9038142). Once the granule precursor has been completely loaded, active PRKD1 phosphorylates ARFIP1 and releases it from ARFs (PubMed:22981988). In turn, ARFs induce fission (PubMed:22981988). Through this mechanism, ensures proper secretory granule formation at the Golgi of pancreatic beta cells (PubMed:22981988)","subcellular_location":"Golgi apparatus; Golgi apparatus, trans-Golgi network membrane","url":"https://www.uniprot.org/uniprotkb/P53367/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ARFIP1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000164144","cell_line_id":"CID000677","localizations":[{"compartment":"golgi","grade":3},{"compartment":"cytoplasmic","grade":1},{"compartment":"vesicles","grade":1}],"interactors":[{"gene":"ARFIP2","stoichiometry":10.0},{"gene":"ARL1","stoichiometry":0.2},{"gene":"HAUS7","stoichiometry":0.2},{"gene":"HAUS2","stoichiometry":0.2},{"gene":"HAUS6","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID000677","total_profiled":1310},"omim":[{"mim_id":"605928","title":"ADP-RIBOSYLATION FACTOR-INTERACTING PROTEIN 1; ARFIP1","url":"https://www.omim.org/entry/605928"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Golgi apparatus","reliability":"Supported"},{"location":"Vesicles","reliability":"Supported"},{"location":"Nucleoplasm","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/ARFIP1"},"hgnc":{"alias_symbol":["HSU52521"],"prev_symbol":[]},"alphafold":{"accession":"P53367","domains":[{"cath_id":"1.20.1270.60","chopping":"173-357","consensus_level":"medium","plddt":95.4864,"start":173,"end":357}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P53367","model_url":"https://alphafold.ebi.ac.uk/files/AF-P53367-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P53367-F1-predicted_aligned_error_v6.png","plddt_mean":75.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ARFIP1","jax_strain_url":"https://www.jax.org/strain/search?query=ARFIP1"},"sequence":{"accession":"P53367","fasta_url":"https://rest.uniprot.org/uniprotkb/P53367.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P53367/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P53367"}},"corpus_meta":[{"pmid":"9038142","id":"PMC_9038142","title":"Arfaptin 1, a putative cytosolic target protein of ADP-ribosylation factor, is recruited to Golgi membranes.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9038142","citation_count":97,"is_preprint":false},{"pmid":"22981988","id":"PMC_22981988","title":"The BAR domain protein Arfaptin-1 controls secretory granule biogenesis at the trans-Golgi network.","date":"2012","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/22981988","citation_count":77,"is_preprint":false},{"pmid":"21239483","id":"PMC_21239483","title":"Arfaptins are localized to the trans-Golgi by interaction with Arl1, but not Arfs.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21239483","citation_count":44,"is_preprint":false},{"pmid":"9989604","id":"PMC_9989604","title":"Arfaptin 1, an ARF-binding protein, inhibits phospholipase D and endoplasmic reticulum/Golgi protein transport.","date":"1999","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/9989604","citation_count":24,"is_preprint":false},{"pmid":"28854360","id":"PMC_28854360","title":"Spatiotemporal Control of Lipid Conversion, Actin-Based Mechanical Forces, and Curvature Sensors during Clathrin/AP-1-Coated Vesicle Biogenesis.","date":"2017","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/28854360","citation_count":24,"is_preprint":false},{"pmid":"9694811","id":"PMC_9694811","title":"Effects of arfaptin 1 on guanine nucleotide-dependent activation of phospholipase D and cholera toxin by ADP-ribosylation factor.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9694811","citation_count":23,"is_preprint":false},{"pmid":"10413101","id":"PMC_10413101","title":"Arfaptin 1 forms a complex with ADP-ribosylation factor and inhibits phospholipase D.","date":"1999","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/10413101","citation_count":21,"is_preprint":false},{"pmid":"12606037","id":"PMC_12606037","title":"Arfaptin 1 inhibits ADP-ribosylation factor-dependent matrix metalloproteinase-9 secretion induced by phorbol ester in HT 1080 fibrosarcoma cells.","date":"2003","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/12606037","citation_count":12,"is_preprint":false},{"pmid":"25789876","id":"PMC_25789876","title":"Arfaptin-1 negatively regulates Arl1-mediated retrograde transport.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25789876","citation_count":8,"is_preprint":false},{"pmid":"16413282","id":"PMC_16413282","title":"Assays and properties of arfaptin 2 binding to Rac1 and ADP-ribosylation factors (Arfs).","date":"2005","source":"Methods in enzymology","url":"https://pubmed.ncbi.nlm.nih.gov/16413282","citation_count":5,"is_preprint":false},{"pmid":"23749176","id":"PMC_23749176","title":"Saving the neck from scission.","date":"2013","source":"Communicative & integrative biology","url":"https://pubmed.ncbi.nlm.nih.gov/23749176","citation_count":5,"is_preprint":false},{"pmid":"23525454","id":"PMC_23525454","title":"Inhibition of formyl peptide-stimulated phospholipase D activation by Fal-002-2 via blockade of the Arf6, RhoA and protein kinase C signaling pathways in rat neutrophils.","date":"2013","source":"Naunyn-Schmiedeberg's archives of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/23525454","citation_count":3,"is_preprint":false}],"cost":{"stage1":{"sonnet_model":"claude-sonnet-4-6","sonnet_input_tokens":7948,"sonnet_output_tokens":2607,"sonnet_usd":0.0629,"sonnet_elapsed_seconds":44.8,"stage1_stop_reason":"end_turn"},"stage2":{"opus_model":"claude-opus-4-8","opus_input_tokens":9722,"opus_output_tokens":3056,"opus_usd":0.125,"opus_elapsed_seconds":38.7,"stage2_stop_reason":"end_turn"},"total_usd":0.1879},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"Arfaptin-1 was identified as a cytosolic binding partner of GTP-bound class I ARFs (especially ARF1) via yeast two-hybrid screening; it binds preferentially to the GTP-bound form of ARF1/ARF3 independent of ARF myristoylation, and is recruited from cytosol to Golgi membranes in a GTPγS-dependent, brefeldin A-sensitive manner. When expressed in COS cells, arfaptin-1 localizes to the Golgi complex.\",\n      \"method\": \"Yeast two-hybrid, recombinant protein binding assays, subcellular fractionation, COS cell overexpression with immunofluorescence\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal binding assays, subcellular fractionation, and localization in multiple systems; foundational paper replicated by subsequent work\",\n      \"pmids\": [\"9038142\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Arfaptin-1 inhibits ARF1/ARF3-stimulated phospholipase D and cholera toxin ADP-ribosyltransferase activities in a concentration-dependent manner in vitro; inhibition requires the N-terminal region of ARF1, and arfaptin-1 has minimal effects on guanine nucleotide binding to ARFs or on GEF/GAP activity.\",\n      \"method\": \"In vitro enzymatic assays with recombinant proteins, ARF deletion/mutant analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro enzymatic assays with mutagenesis controls, replicated in subsequent papers\",\n      \"pmids\": [\"9694811\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Arfaptin-1 overexpression in NIH 3T3 cells inhibits phorbol ester-stimulated phospholipase D activity and ARF activation of Golgi-associated PLD; overexpression also decreases the rate of ER-to-Golgi protein transport (VSV-G glycosylation assay), approximately two-fold.\",\n      \"method\": \"Overexpression in NIH 3T3 cells, PLD activity assay, VSV-G glycosylation transport assay\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-based loss-of-function/gain-of-function with defined cellular readouts, single lab\",\n      \"pmids\": [\"9989604\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Arfaptin-1 associates with high-speed membranes independently of ARF, and myristoylated ARF3 enhances this membrane association, indicating formation of an arfaptin-1/ARF complex on Golgi membranes. Deletion mutagenesis identified two binding sites on arfaptin-1 required for both ARF3 association and inhibition of PLD activation.\",\n      \"method\": \"Membrane fractionation, co-immunoprecipitation, deletion mutagenesis, in vitro PLD assay\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — membrane fractionation with deletion mutants and in vitro PLD assay, single lab\",\n      \"pmids\": [\"10413101\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Arfaptin-1 overexpression inhibits PMA-stimulated MMP-9 secretion and PLD activation in HT1080 fibrosarcoma cells, placing arfaptin-1 upstream of ARF-dependent PLD activation in phorbol ester-stimulated secretion.\",\n      \"method\": \"Overexpression in HT1080 cells, MMP-9 secretion assay, PLD activity assay\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — overexpression with defined secretion readout, consistent with prior mechanistic work, single lab\",\n      \"pmids\": [\"12606037\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Only GTP-bound forms of Arf1, Arf5, and Arf6 interact with arfaptin-1 (GTP-Arf1 showing strongest binding); neither GTP-Rac1 nor GDP-Rac1 binds arfaptin-1, distinguishing arfaptin-1 from arfaptin-2 which binds GDP-Rac1.\",\n      \"method\": \"In vitro binding assays with GTP- and GDP-liganded Arf and Rac1 isoforms\",\n      \"journal\": \"Methods in enzymology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct in vitro binding assays with nucleotide-loaded GTPases, single lab, methods chapter\",\n      \"pmids\": [\"16413282\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Arfaptins (including arfaptin-1) associate with trans-Golgi membranes via their BAR domain interacting with Arl1 (not ARFs); arfaptins compete with golgin-97 and golgin-245 for Arl1 binding. Time-lapse imaging shows arfaptin-1 (but not golgin-97) is incorporated into vesicular and tubular structures emanating from the Golgi, indicating a role in membrane deformation at the TGN.\",\n      \"method\": \"Co-immunoprecipitation, BAR domain deletion mutants, siRNA knockdown, time-lapse fluorescence microscopy\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, domain mapping, live imaging, multiple orthogonal methods in one study\",\n      \"pmids\": [\"21239483\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Protein kinase D (PKD) phosphorylates arfaptin-1 at serine 132, disrupting its ability to inhibit ARF activity and thereby controlling scission of nascent secretory granules at the TGN. Non-phosphorylatable arfaptin-1 (S132A) causes granule scission defects in pancreatic β cells and abolishes glucose-stimulated insulin secretion; arfaptin-1 depletion generates small, non-functional secretory granules.\",\n      \"method\": \"In vitro kinase assay, phosphomimetic/phospho-deficient mutagenesis, RNAi knockdown, insulin secretion assay, electron microscopy of β cells\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro kinase assay with mutagenesis, RNAi, and functional secretion readout in multiple cell types; replicated in commentary\",\n      \"pmids\": [\"22981988\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Arfaptin-1 negatively regulates Arl1-mediated retrograde transport from endosomes to the Golgi (Shiga toxin subunit B assay); knockdown of arfaptin-1 accelerates retrograde transport, while overexpression inhibits it. An Arl1-binding-defective mutant (arfaptin-1b-F317A) fails to inhibit transport, establishing that Arl1 interaction is required. The N-terminal region of arfaptin-1 is involved in retrograde transport regulation.\",\n      \"method\": \"siRNA knockdown, overexpression of WT and Arl1-binding-defective mutants, Shiga toxin subunit B retrograde transport assay, differential affinity chromatography/mass spectrometry\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function and gain-of-function with defined transport assay, mutant rescue experiment, and biochemical identification of interaction\",\n      \"pmids\": [\"25789876\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"BAR-domain-containing arfaptin-1/2 are recruited to tubular membrane intermediates at the TGN and guide clathrin/AP-1-coated carrier scission, downstream of PIP5K1A/PLC-β3-mediated lipid conversion and F-actin-based membrane tubulation.\",\n      \"method\": \"In vitro reconstitution, quantitative proteomics, lipidomics, in vivo cell-based assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution and proteomics, but arfaptin-1 specific contribution not isolated from arfaptin-2 in single study\",\n      \"pmids\": [\"28854360\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"Arfaptin-1 is a BAR-domain-containing cytosolic protein that is recruited to the trans-Golgi network by binding GTP-Arf1 (and related class I ARFs) and Arl1; it inhibits ARF-stimulated phospholipase D and ARF-dependent vesicle scission, thereby acting as a checkpoint that delays secretory granule scission at the TGN until protein kinase D phosphorylates it at serine 132, releasing ARF inhibition and allowing scission to proceed, and it also negatively regulates Arl1-mediated retrograde endosome-to-Golgi transport through its BAR domain.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"Arfaptin-1 (ARFIP1) is a cytosolic BAR-domain protein that functions at the trans-Golgi network as a GTPase-effector regulator of membrane deformation and carrier scission in the secretory and retrograde transport pathways [#0, #6]. It was first defined as a selective effector of GTP-bound class I ARFs, binding preferentially to the activated, GTP-loaded forms of ARF1/ARF3 (and ARF5/ARF6) independent of myristoylation and translocating from cytosol to Golgi membranes in a GTPγS-dependent, brefeldin A-sensitive manner [#0, #5]. Through this interaction it acts as a negative regulator of ARF function, inhibiting ARF-stimulated phospholipase D and cholera toxin ADP-ribosyltransferase activities in a manner requiring the ARF N-terminus, and dampening ARF/PLD-dependent secretory output in cells [#1, #2, #4]. At the TGN its BAR domain additionally binds Arl1—competing with golgins for this site—and incorporates arfaptin-1 into nascent vesicular and tubular carriers, where it negatively regulates Arl1-dependent retrograde endosome-to-Golgi transport and contributes to clathrin/AP-1 carrier scission downstream of phosphoinositide conversion and actin-based tubulation [#6, #8, #9]. Arfaptin-1 operates as a scission checkpoint: protein kinase D phosphorylates it at serine 132 to relieve its inhibition of ARF activity, and loss of this regulation produces secretory granule scission defects and abolishes glucose-stimulated insulin secretion in pancreatic β cells [#7].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Established arfaptin-1 as a bona fide ARF effector by showing it is a cytosolic protein that selectively recognizes the activated state of class I ARFs and is recruited to the Golgi accordingly.\",\n      \"evidence\": \"Yeast two-hybrid, recombinant binding assays, subcellular fractionation, and COS-cell immunofluorescence\",\n      \"pmids\": [\"9038142\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the functional consequence of ARF binding\", \"BAR-domain structural basis of membrane recruitment not addressed\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Defined arfaptin-1 as a negative regulator of ARF enzymatic output, showing it inhibits ARF-stimulated PLD and ADP-ribosyltransferase without altering ARF nucleotide cycling.\",\n      \"evidence\": \"In vitro enzymatic assays with recombinant proteins and ARF deletion/mutant analysis\",\n      \"pmids\": [\"9694811\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cellular relevance of in vitro inhibition not yet established\", \"Mechanism by which the ARF N-terminus mediates inhibition unresolved\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Connected arfaptin-1's ARF/PLD inhibition to cellular transport and secretion, and mapped the arfaptin-1 regions required for ARF binding and inhibition.\",\n      \"evidence\": \"Overexpression in NIH 3T3 and HT1080 cells with PLD, VSV-G glycosylation, and MMP-9 secretion readouts; membrane fractionation with deletion mutants\",\n      \"pmids\": [\"9989604\", \"10413101\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Effects rely on overexpression in single labs\", \"Whether endogenous arfaptin-1 sets the same set-point not tested\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Refined effector specificity, confirming arfaptin-1 binds only GTP-loaded ARFs and not Rac1, distinguishing it from the GDP-Rac-binding paralog arfaptin-2.\",\n      \"evidence\": \"In vitro binding assays with nucleotide-loaded Arf and Rac1 isoforms\",\n      \"pmids\": [\"16413282\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Methods-chapter data from a single lab\", \"Functional consequence of isoform-specific binding not addressed\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identified a distinct BAR-domain-dependent Arl1 interaction and direct role in membrane deformation, repositioning arfaptin-1 as a carrier-shaping factor at the TGN rather than purely an ARF inhibitor.\",\n      \"evidence\": \"Co-IP, BAR-domain deletion mutants, siRNA knockdown, and time-lapse imaging of Golgi carriers\",\n      \"pmids\": [\"21239483\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How ARF binding and Arl1 binding are coordinated unclear\", \"Cargo carried by arfaptin-positive carriers not defined\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Revealed the regulatory switch controlling arfaptin-1 activity, showing PKD phosphorylation at Ser132 relieves ARF inhibition to permit secretory granule scission, with physiological consequences for insulin secretion.\",\n      \"evidence\": \"In vitro kinase assay, phospho-mutant analysis, RNAi, insulin secretion assay, and EM of β cells\",\n      \"pmids\": [\"22981988\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural effect of Ser132 phosphorylation on the ARF-binding surface not resolved\", \"Whether the same switch governs constitutive (non-granule) carriers untested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Extended arfaptin-1 function to the retrograde pathway, demonstrating it negatively regulates Arl1-dependent endosome-to-Golgi transport via a required Arl1-binding interface.\",\n      \"evidence\": \"siRNA knockdown, WT/Arl1-binding-defective mutant rescue, Shiga toxin B retrograde assay, and affinity chromatography/MS\",\n      \"pmids\": [\"25789876\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking Arl1 binding to retrograde rate control unclear\", \"Interplay between anterograde scission and retrograde regulation not integrated\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Placed arfaptins within a lipid- and actin-driven carrier biogenesis pathway, showing BAR-domain recruitment guides clathrin/AP-1 carrier scission downstream of phosphoinositide conversion and F-actin tubulation.\",\n      \"evidence\": \"In vitro reconstitution, quantitative proteomics, lipidomics, and cell-based assays\",\n      \"pmids\": [\"28854360\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Arfaptin-1-specific contribution not separated from arfaptin-2\", \"Quantitative ordering of lipid, actin, and BAR steps not fully resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How arfaptin-1's two GTPase interfaces (GTP-ARF inhibition versus Arl1/BAR-domain membrane shaping) are spatially and temporally coordinated at the TGN, and the structural basis of the PKD-phosphorylation switch, remain open.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structure of arfaptin-1 bound to ARF or Arl1 in the corpus\", \"Endogenous cargo selectivity of arfaptin-1 carriers undefined\", \"Non-secretory physiological roles uncharacterized\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [1, 2, 7]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [6, 9]},\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [6, 9]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [0, 6]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [6, 7, 8, 9]},\n      {\"term_id\": \"R-HSA-9609507\", \"supporting_discovery_ids\": [8]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"ARF1\", \"ARF3\", \"ARL1\", \"PRKD1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win"}}